Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice
Open Access
- 12 December 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (3), 505-517
- https://doi.org/10.1093/ndt/gfs526
Abstract
Fabry disease (FD) is an X-linked disorder of glycosphingolipid catabolism resulting in the accumulation of glycolipids including globotriaosylceramide in cells of various tissues resulting in end-organ manifestations. Initially, FD is typically characterized by angiokeratoma and recurrent episodes of neuropathic pain in the extremities occurring during childhood or adolescence. Most affected patients also exhibit a decreased ability to sweat. Later in life, FD results in left ventricular hypertrophy, proteinuria, renal failure and stroke. These later disease manifestations are non-specific and also common in diabetes, hypertension and atheromatosis and thus for most practitioners do not point into the direction of FD. As a consequence, FD is under-diagnosed and screening of high-risk groups is important for case finding, as is a thorough pedigree analysis of affected patients. In the nephrology clinic, we suggest to screen patients for FD when there is unexplained chronic kidney disease in males younger than 50 years and females of any age. In men, this can be performed by measuring α-galactosidase A activity in plasma, white blood cells or dried blood spots. In women, mutation analysis is necessary, as enzyme measurement alone could miss over one-third of female Fabry patients. A multidisciplinary team should closely monitor all known Fabry patients, with the nephrologist screening kidney impairment (glomerular filtration rate and proteinuria) on a regular basis. Transplanted Fabry patients have a higher mortality than the regular transplant population, but have acceptable outcomes, compared with Fabry patients remaining on dialysis. It is unclear whether enzyme replacement therapy (ERT) prevents deterioration of kidney function. In view of the lack of compelling evidence for ERT, and the low likelihood that a sufficiently powered randomized controlled trial on this topic will be performed, data of all patients with FD should be collected in a central registry.This publication has 70 references indexed in Scilit:
- Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatmentNephrology Dialysis Transplantation, 2012
- European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP)Nephrology Dialysis Transplantation, 2008
- Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype1Kidney International, 2003
- Natural History and Treatment of Renal Involvement in Fabry DiseaseJournal of the American Society of Nephrology, 2002
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseThe New England Journal of Medicine, 2001
- Enzyme Replacement Therapy in Fabry DiseaseJAMA, 2001
- An Atypical Variant of Fabry's Disease in Men with Left Ventricular HypertrophyThe New England Journal of Medicine, 1995
- An Atypical Variant of Fabry's Disease with Manifestations Confined to the MyocardiumThe New England Journal of Medicine, 1991
- Fabry's Disease: Alpha-Galactosidase DeficiencyScience, 1970
- Enzymatic Defect in Fabry's DiseaseThe New England Journal of Medicine, 1967